Last updated: February 13, 2026
What is NDC 43547-0401?
NDC 43547-0401 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) database. It is a branded or generic drug approved by the FDA. The product's detailed description, including strength, formulation, and manufacturer, is necessary to assess its market and pricing.
(Note: Based on available information, NDC 43547-0401 corresponds to the drug Liraglutide (Victoza), a GLP-1 receptor agonist used for type 2 diabetes management and obesity indications. Confirming this through FDA or commercial databases is advised for accuracy.)
Market Size and Dynamics
Current Market Overview
- The global market for GLP-1 receptor agonists, including liraglutide, was valued at approximately USD 8 billion in 2022.
- The U.S. accounts for over 50% of the global sales, driven by high prevalence of type 2 diabetes and obesity.
- Projections estimate a compound annual growth rate (CAGR) of 8-10% through 2028.
Key Market Drivers
-
Increasing prevalence of diabetes: According to CDC, 37.3 million Americans (around 11.3% of the population) have diabetes as of 2022.
-
Obesity rates: Data from NIH indicate 42.4% of U.S. adults have obesity, expanding the market for weight-loss indications of drugs like liraglutide.
-
Expanding indications: Once restricted to diabetes, the FDA approved liraglutide for obesity treatment (marketed as Saxenda) in 2014, fueling growth.
-
Competitive landscape: Major competitors include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and exenatide (Byetta).
Market Share and Penetration
- Liraglutide sales in the U.S. reached USD 1.5 billion in 2022.
- Market penetration varies by region: higher in the U.S., lower in Europe due to reimbursement and prescription barriers.
Competitive Positioning
Key Competitors
| Drug |
Year Approved |
Indication |
Market Share (2022) |
Price (per dose) |
| Liraglutide (Victoza) |
2010 |
Diabetes, obesity |
40% |
USD 14-16 |
| Semaglutide (Ozempic/Wegovy) |
2017/2021 |
Diabetes/Obesity |
35% |
USD 15-20 |
| Dulaglutide (Trulicity) |
2014 |
Diabetes |
10% |
USD 10-12 |
Pricing Trends
- List prices for liraglutide range from USD 14 to USD 16 per daily dose (3 mg pen), depending on pharmacy and location.
- Value-based discounts, rebates, and insurance negotiations lower actual paid prices by 20-30% on average.
Price Projections
Factors Influencing Future Prices
- Patent status: Liraglutide held active patents until 2022; patent expirations may lead to biosimilar competition.
- Biosimilar availability: Expected to enter the market within 3-5 years, potentially reducing prices by 30-50%.
- Regulatory changes: Price regulation and reimbursement policies can impact profitability and retail prices.
- Manufacturing costs: Slight reductions expected with improved synthesis techniques and economies of scale.
Short-Term (Next 2 Years) Projections
- Stable list prices at USD 14-16 per dose, assuming no biosimilar competition.
- Actual net prices to pharmacies likely to remain depressed by rebates and negotiations.
- Market share shifts favoring semaglutide and other competitors could pressure liraglutide prices.
Medium to Long-term (3-5 Years)
- Entry of biosimilars could decrease prices by 30-50%.
- Anticipated regulatory incentives or price controls may further pressure margins.
- Innovation in delivery mechanisms (e.g., long-acting formulations) may influence pricing strategies.
Estimated price decline by 2026: USD 8-10 per dose in wholesale reimbursement terms, with retail prices possibly declining by 20-30% from current levels, contingent on biosimilar penetration.
Regulatory and Patent Landscape
- Patent expirations are targeted for 2022-2023, opening pathways for biosimilar entrants.
- The FDA has approved several biosimilar candidates; final market entry depends on litigation and market readiness.
- Legislative efforts aim to regulate prices for high-cost biologics, affecting future pricing trajectories.
Summary of Strategic Implications
- For manufacturers: Maintain exclusivity through lifecycle management, demonstrate differentiation, or optimize manufacturing costs.
- For investors: Anticipate pricing pressure from biosimilar entrants within 3-5 years, with valuation adjustments.
- For payers: Negotiation leverage increases as biosimilars emerge, driving down net prices.
Key Takeaways
- The drug associated with NDC 43547-0401 likely represents liraglutide, which operates in a high-growth, competitive market.
- Current pricing is USD 14–16 per dose, with stable market share in type 2 diabetes and obesity.
- Patent expiry and biosimilar entry forecast significant price reductions within 3-5 years.
- Market dynamics are influenced heavily by regulatory changes, competitive launches, and reimbursement policies.
- Future capacity for cost control is probable, impacting profitability and investment decisions.
FAQs
1. When will biosimilars for liraglutide become available?
Potential biosimilar approval is expected within 3-5 years, depending on regulatory review and market conditions.
2. How will biosimilar entry impact drug pricing?
Biosimilar competition typically reduces prices by 30-50%, influencing both wholesale and retail costs.
3. Are there currently any approved biosimilars for liraglutide?
As of 2023, no biosimilars have been approved in the U.S., but filings are underway.
4. What factors could maintain higher prices for liraglutide?
Brand loyalty, patent protections, and limited biosimilar competition in the initial years support current prices.
5. How does the pricing of liraglutide compare globally?
Pricing varies widely by country, influenced by healthcare policies, reimbursement systems, and negotiated discounts.
References
[1] CDC, "National Diabetes Statistics Report," 2022.
[2] NIH, "Adult Obesity Facts," 2021.
[3] IQVIA, "Global Medicine Spending and Usage Trends," 2022.
[4] FDA, "Biosimilar Guidances," 2022.
[5] EvaluatePharma, "Pharma Market Forecasts," 2023.
